Friday, February 12, 2016

Transition Therapeutics reports TT401 trial results

Transition Therapeutics reports TT401 trial results

February 1, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects […]

Can-Fite receives patent notice for sexual dysfunction drug

Can-Fite receives patent notice for sexual dysfunction drug

January 19, 2016 by · Leave a Comment 

Tweet Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The composition of matter patent protects the use of Can-Fite’s proprietary A3 Adenosine Receptor (A3AR) modulator, including the preparation of its pharmaceutical compositions and its use in […]

ReVENT Medical prepares for U.S. pivotal trial in sleep apnea

ReVENT Medical prepares for U.S. pivotal trial in sleep apnea

November 24, 2015 by · Leave a Comment 

Tweet Closely-held ReVENT Medical expects to begin a U.S. pivotal trial in the first half next year with its minimally invasive surgical solution to treat obstructive sleep apnea (OSA). “OSA is the most common type of sleep apnea and is caused by an obstruction of the upper airway, originating in the palate and/or the tongue,” […]

Can-Fite expands development of CF102 into NASH

Can-Fite expands development of CF102 into NASH

November 23, 2015 by · Leave a Comment 

Tweet Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into the treatment for non-alcoholic steatohepatitis (NASH). NASH is characterized by excess fat in the liver along with inflammation and liver damage. While it resembles […]

Leerink starts Tobira Therapeutics at outperform

Leerink starts Tobira Therapeutics at outperform

October 23, 2015 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with an “outperform” rating and $24 price target in 12 months. The stock closed at $9.26 on Thursday. Tobira is aiming to capture the lion’s share of the currently untapped non-alcoholic steatohepatitis (NASH) market with Cenicriviroc (CVC), an oral, once-daily immunomodulator which directly targets inflammation […]

MOA of Can-Fite’s CF602 can improve sexual dysfunction

MOA of Can-Fite’s CF602 can improve sexual dysfunction

October 22, 2015 by · Leave a Comment 

Tweet Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its CF602 drug candidate showing a defined mechanism of action in erectile dysfunction similar to sildenafil (Viagra) in a rat model of diabetes mellitus. Based on these latest findings, Can-Fite plans to file an IND with the FDA for CF602 in the third quarter […]

Rodman starts Oramed at buy

Rodman starts Oramed at buy

October 1, 2015 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMD) with a “buy” rating and $24 price target. The stock closed at $5.47 on Wednesday. “Oramed constitutes a differentiated take on diabetes therapy, focusing on oral delivery of existing therapeutic agents like insulin and exenatide,” writes analyst Raghuram Selvaraju. He considers Oramed an attractive […]

Oramed gets patent for oral administration of proteins

Oramed gets patent for oral administration of proteins

September 24, 2015 by · Leave a Comment 

Tweet The United States Patent and Trademark Office has approved Oramed Pharmaceuticals’ (NASDAQ: ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” In a statement, CEO, Nadav Kidron, said the patent is an important milestone, paving the way for the company’s entrance into the U.S. diabetes market, which is the […]

Stifel starts vTv Therapeutics at buy

Stifel starts vTv Therapeutics at buy

August 24, 2015 by · Leave a Comment 

Tweet Stifel has initiated coverage of vTv Therapeutics (NASDAQ:VTVT) with a “buy” rating and $17 price target, pointing to its significant Alzheimer’s disease (AD) and diabetes assets. The stock closed at $8.85 on Friday. “Unlike many of its predecessors, the company remained private and in stealth mode for two decades before going public with three […]

M Pharma advancing technologies for obesity and diabetes

M Pharma advancing technologies for obesity and diabetes

July 7, 2015 by · Leave a Comment 

Tweet M Pharmaceutical (OTCQB:MPHMF; CSE:MQ; FWB:T3F1.F) is advancing a family of biomedical technologies to manage obesity – TriMeo and TriMtec – and eMosquito to manage diabetes. “All three of our technologies represent a spectrum of solutions with reduced invasiveness and enhanced effectiveness than currently available approved solutions,” Dr. Martin Mintchev, president and CEO, says in […]

Next Page »

Email Newsletters with Constant Contact
Google+